TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of nonsegmental vitiligo.~* History of prior vitiligo treatment with a total duration of at least 3 months.~* Agreement to discontinue all agents and procedures used to treat vitiligo from screening through the final safety follow-up visit.~* Willingness to avoid pregnancy or fathering children~* Further inclusion criteria apply.~Exclusion Criteria:~* Other forms of vitiligo (eg, segmental) or other skin depigmentation disorders.~* Uncontrolled thyroid function at screening as determined by the investigator.~* Women who are pregnant (or who are considering pregnancy) or lactating.~* Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator.~* Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis.~* Participants known to be infected with HIV, Hepatitis B, or Hepatitis C.~* Laboratory values outside of the protocol-defined ranges.~* Further exclusion criteria apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- INCB054707 Dose A followed by Dose C (Type: EXPERIMENTAL): Participants will receive INCB054707 Dose A for 24 weeks (Period 1) followed by INCB054707 Dose C for 28 weeks (Period 2).
- INCB054707 Dose B (Type: EXPERIMENTAL): Participants will receive INCB054707 Dose B for 52 weeks (Period 1 + Period 2).
- INCB054707 Dose C (Type: EXPERIMENTAL): Participants will receive INCB054707 Dose C for 52 weeks (Period 1 + Period 2).
- Placebo followed by INCB054707 Dose C (Type: PLACEBO_COMPARATOR): Participants will receive placebo for 24 weeks (Period 1) followed by INCB054707 Dose C for 28 weeks (Period 2).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lipoprotein Apheresis in Refractory Angina Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with refractory angina for more than three months.~* Two or more episodes of angina per week.~* Previous history of myocardial infarction, coronary artery bypass graft (CABG) surgery,percutaneous coronary intervention (PCI) or any combination of the above.~* Prescribed optimal medical therapy.~* Hypercholesterolaemia with an elevated Lp(a) \> 50mg/dL and an LDL-cholesterol less than 4.0mmol/L despite optimal lipid lowering drug therapy.~Exclusion Criteria:~* Patients with poor calibre veins for cannulation.~* Patients with any other chronic systemic illness such as liver or renal failure, neoplastic disease, overt cardiac failure, unstable coronary artery disease, coronary revascularisation or a myocardial infarction within the previous eight weeks.~* Pregnancy, untreated diabetes mellitus, untreated arterial hypertension, and those with general contraindications to undergoing Cardiovascular magnetic resonance imaging or contraindications to adenosine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- First Lipoprotein Apheresis, then sham apheresis (Type: ACTIVE_COMPARATOR): Three months of weekly lipoprotein apheresis, 1 month washout, then three month sham apheresis
- First Sham Apheresis, then Lipoprotein Apheresis (Type: SHAM_COMPARATOR): Three months of weekly sham apheresis, 1 month washout, then three month lipoprotein Apheresis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ZIPS Study - Zip Incision aPproximation vs. Suture

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients 18 years of age and older;~2. Patients requiring suture closure for epidermal closure (after placement of cardiac implantable electronic devices; including de novo and re implant generator changes);~3. Patients willing and able to complete study protocol~4. Life expectancy greater than 1 year~Exclusion Criteria:~1. Known bleeding disorder not caused by medication;~2. Known personal or family history of keloid formation or scar hypertrophy;~3. Known allergy or hypersensitivity to non-latex skin adhesives;~4. Atrophic skin deemed clinically prone to blistering;~5. Any skin disorder affecting wound healing;~6. Any other condition that in the opinion of the investigator would make a particular subject unsuitable for this study.~7. Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zip Surgical Skin Closure device (Type: EXPERIMENTAL): The Zip Surgical Skin Closure device is a single use, sterile medical device that replaces sutures, staples, and glue for closure of the skin layer for surgical incisions or laceration repair. The device will applied by the surgeon at the end of the CIED procedure and be worn until the two week post-operative wound check.
- Standard Suture Closure (Type: ACTIVE_COMPARATOR): The surgeon will perform standard suture closure for the skin layer following CIED procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Less than or equal to 1000 gm. birth weight~* Less than or equal to 30 weeks gestational age~* Day 7-14 of life~* Intubated and mechanically ventilated at any time days 7-14 of life~Exclusion Criteria:~* Serious congenital malformations~* Life expectancy less than 7 days from enrollment~* Previous treatment with iNO~* Active pulmonary hemorrhage at time of enrollment~* Active air leak syndrome at time of enrollment~* Bilateral grade IV intracranial hemorrhage prior to enrollment~* Less than 48 hours from last clinical dose of early surfactant.

- Gender: ALL
- Minimum Age: 7 Days
- Maximum Age: 14 Days
- Healthy Volunteers: f

Study Arms:
- Treatment Surfactant (Infasurf) ONY, NY (Type: ACTIVE_COMPARATOR): Patients receive inhaled nitric oxide and scheduled doses of Infasurf on study days 0, 3, 7, 10, and 14, if infant remains ventilated.
- Sham (no treatment) (Type: PLACEBO_COMPARATOR): Infants receiving inhaled nitric oxide will receive Sham (no treatment) on study days 0, 3, 7, 10, and 14, if infant remains ventilated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented multiple myeloma according to protocol-defined criteria~* Evidence of disease progression on the most recent prior treatment regimen based on International Myeloma Working Group criteria~* Eastern Cooperative Oncology Group performance status score of 0, 1, or 2~* Laboratory values and electrocardiogram within protocol-defined parameters at screening~Exclusion Criteria:~* Received daratumumab or other anti-CD38 therapies previously~* Nonsecretory multiple myeloma~* Previously received an allogenic stem cell transplant or has received an autologous stem cell transplantation within 12 weeks~* Exhibiting clinical signs of meningeal involvement of multiple myeloma~* Known chronic obstructive pulmonary disease, persistent asthma, or a history of asthma within 5 years~* Seropositive for human immunodeficiency virus, hepatitis B or antibodies to hepatitis B surface and core antigens, or hepatitis C~* Has plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or amyloidosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1 (Type: EXPERIMENTAL): During Stage 1 of Part 1, participants will be randomized to receive daratumumab treatment regimens in Group A and Group B. If in Stage 1, 1 or both of the treatment groups is considered to be ineffective and/or not well tolerated, then that treatment group will be terminated. Participants in Group B will be given the option to cross over to Group A if the investigator deems it in the best interest of the participants.
- Part 2 (Type: EXPERIMENTAL): Based on the Part 1 response rate, Group A or B daratumumab treatment will be selected as the treatment regimen for participants enrolled in Part 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Dexamethasone on Sleep Related Breathing Disturbances in Patients With COPD at Altitude

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic obstructive pulmonary disease (COPD), GOLD grade 1-2~* Living at low altitude (\<800m)~Exclusion Criteria:~* COPD exacerbation~* severe COPD, GOLD grade 3 or 4~* arterial oxygen saturation \<92% at low altitude (\<800 m)~* Diabetes, uncontrolled cardiovascular disease such as systemic arterial hypertension, coronary artery disease; previous stroke; pneumothorax in the last 2 months, untreated or symptomatic peptic ulcer disease, glaucoma, obstructive sleep apnea.~* Internal, neurologic or psychiatric disease that interfere with protocol compliance including current heavy smoking (\>20 cigarettes per day).~* pregnant or nursing patients

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Dexamethasone (Type: ACTIVE_COMPARATOR): Dexamethasone 4 mg capsules, twice per day, orally
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsules twice per day, orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Eltrombopag Plus Diacerein vs Eltrombopag in Adult ITP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant must be at least 18 years of age at the time of the screening.~* Participant may be male or female.~* Participant has a confirmed diagnosis of ITP according to the 2019 International Working Group assessment at screening.~* Participant who didn't respond to eltrombopag retreatment (75mg by mouth once a day for 14 days) after eltrombopag previous treatment inefficient or relapsed (platelet count below 30 × 10\^9/L or below 2-fold increase from baseline platelet count, or bleeding).~* Bone marrow biopsy is performed in participants over 60 years to exclude hematological malignancies.~Exclusion Criteria:~* Participant has evidence of a secondary cause of immune thrombocytopenia (e.g. leukemia, lymphoma, common variable immune-deficiency, systemic lupus erythematosus, autoimmune thyroid disease, past medical history of untreated H. pylori infection) or to drug treatments (e.g. heparin, quinine, antimicrobials, anticonvulsants) or participant has a multiple immune cytopenia, e.g. Evan's syndrome.~* Participant has clinically life-threatening bleeding (e.g. central nervous system bleeding, menorrhagia with significant drop in hemoglobin). Participant has a history of coagulopathy disorders other than ITP.~* Participant has a history of arterial or venous thromboembolism (e.g. stroke, transient ischemic attach, myocardial infarction, deep vein thrombosis or pulmonary embolism) within the 6 months prior to randomization or requires anticoagulant treatment.~* Participant has 12-lead ECG with changes considered to be clinically significant upon medical review at baseline.~* Participant has severe renal impairment (glomerular filtration rate less than 45ml/min/1.73 m2).~* Participant has 3 × upper limit of normal of any of the following: alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase.~* Participant has received corticosteroids, rh-TPO, romiplostim, or immunosuppression within 4 weeks before screening.~* Participant with any of the following conditions: severe immunodeficiency, active or previous malignancy, human immunodeficiency virus (HIV), hepatitis B or C virus infection, pregnancy or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combination group (Type: EXPERIMENTAL): Eltrombopag plus diacerein
- Monotherapy group (Type: PLACEBO_COMPARATOR): Eltrombopag monotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of relapsing remitting multiple sclerosis~* At least one relapse in the last two years~Exclusion Criteria:~* Patients treated in the past with total lymphoid irradiation, monoclonal antibody, T cell vaccination, cladribine, bone marrow transplantation, azathioprine, cyclophosphamide, methotrexate, mitoxantrone, cyclosporin or Tysabri~* Clinically significant diseases other than multiple sclerosis

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Estriol plus Copaxone injections QD (Type: ACTIVE_COMPARATOR): Estriol Capsules (daily) plus Copaxone injections (daily). Progestin capsules given for 2 weeks every 3 months to avoid unopposed estrogens.
- Placebo plus Copaxone injections QD (Type: PLACEBO_COMPARATOR): Placebo Capsules (daily) plus Copaxone injections (daily). A second placebo capsule given for 2 weeks every 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combining Antidepressant Medication and Psychotherapy for Insomnia to Improve Depression Outcome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of major depressive disorder~* HRSD(17) score of at least 14~* Presence and complaint of insomnia for at least 1 month~* Fluent in English~* Use of an effective form of contraception throughout the study~Exclusion Criteria:~* Other psychiatric disorders (e.g., bipolar disorder, post traumatic stress disorder, obsessive compulsive disorder, eating disorder)~* Psychotic symptoms~* Serious, unstable, or terminal medical condition~* Axis II diagnosis of antisocial, schizotypal, or severe borderline personality disorder~* Substance abuse~* Not willing to end other psychiatric treatment~* Previous electroconvulsive therapy or vagus nerve stimulation treatment during the last year~* Sleep apnea, restless leg, or periodic limb movement disorder (to be ruled out after first sleep study)~* Other sleep disorders~* Currently pregnant or breastfeeding~* History of seizure disorder~* Disease or condition that produces altered metabolism or hemodynamic responses~* Liver or kidney dysfunction~* Current use of any over the counter medications or herbs for mood or sleep benefits (e.g., melatonin, valerian, kava, hop extract, St. John's Wort, SAMe)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- MED+CBTI (Type: EXPERIMENTAL): Escitalopram plus Cognitive Behavioral Therapy for Insomnia
- MED+CTRL (Type: ACTIVE_COMPARATOR): Escitalopram plus Pseudo-desensitization Therapy for Insomnia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children younger than four years with confirmed cystic fibrosis diagnosis and a body weight of at least 2 kilograms~Exclusion Criteria:~* Ileus or acute abdomen~* history of fibrosing colonopathy~* history of distal ileal obstruction without surgery~* solid organ transplant or surgery affecting the large bowel, other than appendectomy

- Gender: ALL
- Minimum Age: None
- Maximum Age: 4 Years
- Healthy Volunteers: f

Study Arms:
- Creon micro, minimicrospheres (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Empirical Versus Preemptive Antifungal Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)~  * Newly diagnosed disease or disease in first relapse after hematological remission lasting for a minimum of 6 months AND meets one of the following criteria:~    * Starting remission-induction chemotherapy within 3 days prior to study randomization~   * Starting myeloablative conditioning regimen to prepare for a first allogeneic hematopoietic stem cell transplantation within 3 days prior to study randomization~* Planning a hospital admission for the duration of the neutropenic phase (ANC \< 0.5 x 10\^9 /L)~* Planning to receive oral or intravenous fluconazole for Candida prophylaxis at a dose of 400 mg/day~  * Fluconazole is discontinued during caspofungin acetate administration~* No previous or current history of proven or probable invasive fungal disease (IFD)~PATIENT CHARACTERISTICS:~* See Disease Characteristics~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients muse use effective contraception during and for at least 3 months after completion of study therapy~* No current clinical diagnosis of pneumonia~* No serious, uncontrolled, concomitant disease or comorbidity that, in the opinion of the investigator, may compromise adherence to the study protocol~* No history of allergy or any adverse reaction to echinocandin drugs (i.e., caspofungin acetate, micafungin, or anidulafungin)~* No hypersensitivity to caspofungin active substance or to any of the excipients~* No inadequately treated infection~* No documented HIV infection~* No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule~* No history of liver cirrhosis or severe hepatic insufficiency (i.e., Child Pugh Class C, D, or E)~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No concurrent participation on another clinical trial using an investigational drug for infectious diseases~* No other concurrent systemic antifungal therapy (oral or intravenous)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Empirical (Type: ACTIVE_COMPARATOR): Empirical approach (fever driven) for starting antifungal therapy
- Pre-emptive (Type: EXPERIMENTAL): Pre-emptive approach (diagnostic driven) for starting antifungal therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Effectiveness of MK0476 (Montelukast) in Patients With Chronic Asthma (0476-388)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* A person is 15 to 65 years of age. A person has had chronic asthma for at least one year~Exclusion Criteria:~* A person is a smoker or has smoked more that a pack a day for more than 10 years before stopping~* A person has other lung disorders such as COPD (chronic obstructive pulmonary disorder)

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): montelukast Placebo
- 2 (Type: EXPERIMENTAL): montelukast
- 3 (Type: EXPERIMENTAL): montelukast
- 4 (Type: EXPERIMENTAL): montelukast

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Milnacipran for the Treatment of Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of fibromyalgia defined by 1990 American College of Rheumatology (ACR) Criteria~Exclusion Criteria:~* Psychiatric illness~* Depression~* Suicidal risk~* Substance abuse~* Pulmonary dysfunction~* Renal impairment~* Active cardiac disease~* Liver disease~* Autoimmune disease~* Cancer~* Sleep apnea~* Inflammatory bowel disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete